marked.bio: EGFR exon 19 deletion / L858Rhttps://marked.bio/biomarker/egfr-ex19del-l858r/index.html Weekly changes in EGFR exon 19 deletion / L858R trials and approvals.en EGFR exon 19 deletion / L858R, week to 27 October 2026: 1 new trialhttps://marked.bio/biomarker/egfr-ex19del-l858r/index.html#whats-newmarked.bio-egfr_ex19del_l858r-2026-10-27Tue, 27 Oct 2026 12:00:00 +0000<p><b>1 new trial</b> on marked.bio between 20 October 2026 and 27 October 2026.</p><h3>New trials (1)</h3><ul><li><a href="https://clinicaltrials.gov/study/NCT07897188">ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC</a> (Phase 3, Jiangsu Aosaikang Pharmaceutical) <i>EGFR exon 19 deletion / L858R</i></li></ul>